Core Viewpoint - Rhine Biotech plans to change its controlling shareholder to Guangzhou Defu Nutrition, with the resumption of trading on December 24, following a suspension since December 10 [2][5]. Shareholder Changes - On December 22, Rhine Biotech's current controlling shareholder Qin Benjun signed several agreements with Guangzhou Defu Nutrition, including a control change framework agreement and a share transfer agreement [8]. - Qin Benjun will transfer 8.09% of his shares to Guangzhou Defu Nutrition, relinquish 25.50% of his shares, and retain voting rights for 3% of his shares. The total transaction price is 646 million yuan, with a transfer price of 10.76 yuan per share, representing a premium of 23.68% over the closing price of 8.70 yuan on December 9 [8][9]. New Shareholding Structure - After the transaction, Qin Benjun will hold 28.50% of Rhine Biotech's shares and 4.14% of the voting rights, while Guangzhou Defu Nutrition will hold 8.09% of the shares and 11.17% of the voting rights [9]. Strategic Focus - Guangzhou Defu Nutrition, established on December 2, 2025, is controlled by Hou Ming and Li Zhenfu, and aims to leverage its resources in the healthcare sector to enhance Rhine Biotech's operational efficiency and governance structure [10]. Acquisition Plans - Rhine Biotech intends to expand its industry chain through acquisitions, specifically by issuing shares to purchase 80% of Beijing Jinkangpu Food Technology Co., Ltd. from Defu Jinkangpu and Xiamen Defu Jinkangpu [12]. - This acquisition will allow Rhine Biotech to extend its operations into the field of nutritional enhancers, creating a closed-loop industry chain from raw materials to formulation solutions [12]. Financial Overview of Beijing Jinkangpu - As of September 30, 2025, Beijing Jinkangpu reported total assets of 593 million yuan and net assets of 535 million yuan, with net profits of 70.27 million yuan and 40.33 million yuan for 2024 and the first three quarters of 2025, respectively [13][14]. Financial Overview of Rhine Biotech - As of September 30, 2025, Rhine Biotech's total assets were 4.985 billion yuan, and net assets were 3.162 billion yuan, with net profits of 16.3 million yuan and 70.40 million yuan for 2024 and the first three quarters of 2025, respectively [15].

Core Viewpoint - Rhein Biotech is undergoing a change in control, with Guangzhou Defu Nutrition becoming the new controlling shareholder, effective from December 24, following a series of agreements signed on December 22 [1][2]. Shareholding Structure - Prior to the agreement, Qin Benjun held 36.59% of Rhein Biotech's shares and 36.59% of the voting rights. After the transfer, he will hold 28.50% of the shares and 4.14% of the voting rights [2][3]. - Guangzhou Defu Nutrition will acquire 8.09% of Rhein Biotech's shares and 11.17% of the voting rights post-transaction [3]. Financial Details of the Transaction - The total transaction price for the share transfer is 646 million yuan (including tax), with a transfer price of 10.76 yuan per share, representing a premium of 23.68% over the closing price of 8.70 yuan on December 9 [1]. Company Background and Strategy - Guangzhou Defu Nutrition was established on December 2, 2025, and is controlled by Hou Ming and Li Zhenfu. It focuses on the healthcare and consumer sectors [4]. - Rhein Biotech aims to leverage Defu Capital's resources in the healthcare sector to enhance its operational efficiency and governance structure [4]. Expansion Plans - Rhein Biotech plans to expand its industry chain through acquisitions, specifically by purchasing 80% of Beijing Jinkangpu Food Technology Co., Ltd. [6]. - The company intends to create a closed-loop industry chain from raw materials to formulation solutions, enhancing synergy with Beijing Jinkangpu, a leading supplier of nutritional fortifiers [6]. Financial Performance - As of September 30, 2025, Rhein Biotech reported total assets of 4.985 billion yuan and net assets of 3.162 billion yuan [7]. - The company's net profit for the first three quarters of 2025 was approximately 70.40 million yuan [10].

Core Viewpoint - Rhine Biotech is undergoing a change in control, with Guangzhou Defu Nutrition becoming the new controlling shareholder, effective from December 24, following a series of agreements signed on December 22 [2][3]. Shareholder Changes - The controlling shareholder Qin Benjun will transfer 8.09% of his shares to Guangzhou Defu Nutrition and will relinquish 25.50% of his shares while retaining 3% voting rights [2][4]. - After the transaction, Qin Benjun will hold 28.50% of Rhine Biotech's shares and 4.14% of the voting rights [3][4]. Transaction Details - The total transaction price for the share transfer is 646 million yuan (including tax), with a transfer price of 10.76 yuan per share, representing a premium of 23.68% over the closing price of 8.70 yuan on December 9 [2][4]. Company Background - Guangzhou Defu Nutrition was established on December 2, 2025, by Defu Capital and currently has not engaged in any actual business activities [5]. - Defu Capital focuses on the healthcare and consumer sectors, aiming to leverage its resources to enhance Rhine Biotech's operational efficiency and governance structure [5]. Strategic Expansion - Rhine Biotech plans to expand its industry chain through acquisitions, specifically by purchasing 80% of Beijing Jinkangpu Food Technology Co., Ltd. [6]. - The company aims to create a closed-loop industry chain from raw materials to formulation solutions, enhancing business synergy with Beijing Jinkangpu, a leading supplier of nutritional fortifiers [6][8]. Financial Overview - As of September 30, 2025, Rhine Biotech reported total assets of 4.985 billion yuan and net assets of 3.162 billion yuan, with a net profit of 163 million yuan for 2024 and 70.4 million yuan for the first three quarters of 2025 [8][9]. - Beijing Jinkangpu's total assets were reported at 593 million yuan, with a net profit of 70.3 million yuan for 2024 and 40.3 million yuan for the first three quarters of 2025 [7][8].

Group 1 - The company announced a suspension of trading due to a planned change in control and the issuance of shares to acquire assets [1] - The controlling shareholder, Qin Benjun, is negotiating to transfer part of his shares and relinquish voting rights, with agreements signed with major counterparties [1][2] - The transaction will result in Beijing Jinkangpu becoming a subsidiary of the company, included in the consolidated financial statements, and is expected to be an affiliated transaction [2] Group 2 - Guangzhou Defu Nutrition, the acquiring party, was established on December 2, 2025, and has a capital contribution of 1.35 billion yuan, with a significant majority from Guangzhou Defu Investment Management [2] - Beijing Jinkangpu, the target of the acquisition, specializes in food nutrition fortifiers and has been operational since 2004, serving various sectors including infant food and health supplements [2] - The company focuses on the production and operation of natural health products, with expertise in over 300 standardized plant extraction technologies and a range of products including monk fruit and stevia extracts [3] Group 3 - In the first three quarters of the year, the company reported revenue of 1.272 billion yuan, an increase of 8.73%, while net profit attributable to shareholders decreased by 30.73% to 70.3953 million yuan [3] - The transaction is expected to enhance the company's capabilities in product formulation and core competitiveness in the food and health supplement sectors, leveraging synergies between the two entities [3] - The collaboration aims to ensure a supply of natural raw materials and enhance global marketing capabilities, fostering a mutually beneficial development model [3]

Group 1 - The company, Rhine Biology, announced a suspension of trading on December 10, 2025, due to plans for a change in control and the issuance of shares to acquire assets [2][4] - The controlling shareholder, Qin Benjun, is planning to transfer part of his shares and relinquish voting rights, with a control change agreement already signed with key parties [4] - The company intends to acquire 80% of Beijing Jinkangpu's shares through share issuance and raise matching funds from Guangzhou Defu Nutrition [4][5] Group 2 - The transaction aims to integrate Beijing Jinkangpu into the listed company, enhancing synergy in the food and beverage and health product sectors, thereby improving R&D capabilities and market coverage [5] - Rhine Biology specializes in the production of natural health products, focusing on the R&D and production of plant functional ingredients, with over 300 standardized extraction technologies [5] - In the first three quarters of this year, the company reported revenue of 1.272 billion yuan, an increase of 8.73%, while net profit attributable to shareholders fell by 30.73% to 70.3953 million yuan [5]

Core Viewpoint - The participation of CanPrev in the China International Import Expo (CIIE) reinforces the company's confidence in the long-term growth of the Chinese market [1] Group 1: Company Overview - CanPrev, a natural health brand founded in Canada in 1922, is participating in the CIIE for the first time this year as part of the Canadian National Pavilion [1] - The company operates in 45 countries and regions globally and successfully listed on the Toronto Stock Exchange in 2017 [1] - In 2023, CanPrev established its China headquarters and aims to achieve "multinational company regional headquarters" status by May 2025, marking a new phase in its development in China [1] Group 2: Market Insights - The high traffic and live streaming sales atmosphere at the CIIE have increased the company's confidence in the continuous growth of the Chinese market [1] - CanPrev's participation in the expo is seen as an opportunity for brand communication and recognition, as well as a tangible boost to sales [1] - The company launched a globally debut children's lutein product at the expo, showcasing its full product matrix [1] Group 3: Strategic Vision - The CEO of CanPrev emphasized the alignment between the rational awakening of Chinese consumers and the company's long-standing commitment to quality [1] - The CIIE highlights China's high standards and open cooperation, with CanPrev aiming to integrate Canadian production standards with the health needs of Chinese consumers [1] - The company seeks to contribute to the quality upgrade of the global health industry through this integration [1]